MA43503B2 - Arn viral simple brin isole (ssrna) derive du genome du virus de la peste equine (ahsv) pour la vaccination d'animaux contre le ahsv - Google Patents

Arn viral simple brin isole (ssrna) derive du genome du virus de la peste equine (ahsv) pour la vaccination d'animaux contre le ahsv

Info

Publication number
MA43503B2
MA43503B2 MA43503A MA43503A MA43503B2 MA 43503 B2 MA43503 B2 MA 43503B2 MA 43503 A MA43503 A MA 43503A MA 43503 A MA43503 A MA 43503A MA 43503 B2 MA43503 B2 MA 43503B2
Authority
MA
Morocco
Prior art keywords
ahsv
vaccination
derived
arn
ssrna
Prior art date
Application number
MA43503A
Other languages
English (en)
Other versions
MA43503A1 (fr
Inventor
Polly Roy
Original Assignee
London School Of Hyghiene & Tropical Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by London School Of Hyghiene & Tropical Medicine filed Critical London School Of Hyghiene & Tropical Medicine
Publication of MA43503A1 publication Critical patent/MA43503A1/fr
Publication of MA43503B2 publication Critical patent/MA43503B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12151—Methods of production or purification of viral material
    • C12N2720/12152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12161—Methods of inactivation or attenuation
    • C12N2720/12162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un arnsb isolé du virus de la peste du cheval (ahsv) comprenant une pluralité de mutations ; une cellule complémentaire pour la réplication d'une souche virale vaccinale à partir dudit arnsb ; une souche virale vaccinale dérivée dudit arnsb ; l'utilisation de ladite souche virale vaccinale et/ou de l'arnsb isolé dans la vaccination d'un animal contre une infection par ahsv ; un procédé de vaccination comprenant celui-ci ; et une composition pharmaceutique comprenant ladite souche virale vaccinale et/ou ledit arnsb isolé.
MA43503A 2016-04-26 2017-04-10 Arn viral simple brin isole (ssrna) derive du genome du virus de la peste equine (ahsv) pour la vaccination d'animaux contre le ahsv MA43503B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201607196 2016-04-26
PCT/GB2017/050994 WO2017187131A1 (fr) 2016-04-26 2017-04-10 Vaccin contre des reoviridae

Publications (2)

Publication Number Publication Date
MA43503A1 MA43503A1 (fr) 2020-01-31
MA43503B2 true MA43503B2 (fr) 2021-02-26

Family

ID=58548764

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43503A MA43503B2 (fr) 2016-04-26 2017-04-10 Arn viral simple brin isole (ssrna) derive du genome du virus de la peste equine (ahsv) pour la vaccination d'animaux contre le ahsv

Country Status (10)

Country Link
US (1) US10688176B2 (fr)
EP (1) EP3449003B1 (fr)
JP (1) JP7053488B2 (fr)
CN (1) CN109312351B9 (fr)
AU (1) AU2017256071B2 (fr)
CA (1) CA3022392A1 (fr)
IL (1) IL262510B2 (fr)
MA (1) MA43503B2 (fr)
WO (1) WO2017187131A1 (fr)
ZA (1) ZA201807035B (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9301272A (nl) * 1993-07-20 1995-02-16 Aesculaap Bv Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.
CA2377084A1 (fr) * 1999-06-25 2001-01-04 Doris Apt Procedes et compositions pour la mise au point de vaccins attenues
MX2010005701A (es) * 2007-11-26 2010-08-31 London School Of Hygiene & Tro Metodo para producir cepa viral vacunal de un virus de la familia reoviridae.
AU2014201189B2 (en) 2007-11-26 2015-07-09 London School Of Hygiene & Tropical Medicine Method for producing vaccinal viral strain of a virus of the Reoviridae family
EP2747778B1 (fr) * 2011-08-26 2017-12-06 Wisconsin Alumni Research Foundation Virus de la grippe ayant un segment génique pb2 mutant en tant que vaccins vivants atténués
MA37749B1 (fr) * 2012-06-13 2017-05-31 Merial Ltd Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
WO2016071850A1 (fr) 2014-11-04 2016-05-12 Deltamune (Pty) Limited Virus de la peste équine vivant atténué

Also Published As

Publication number Publication date
CN109312351B (zh) 2020-09-01
JP7053488B2 (ja) 2022-04-12
IL262510A (en) 2018-12-31
IL262510B2 (en) 2023-09-01
WO2017187131A1 (fr) 2017-11-02
MA43503A1 (fr) 2020-01-31
US10688176B2 (en) 2020-06-23
ZA201807035B (en) 2019-06-26
AU2017256071B2 (en) 2022-11-17
IL262510B1 (en) 2023-05-01
CA3022392A1 (fr) 2017-11-02
JP2019514366A (ja) 2019-06-06
US20190060442A1 (en) 2019-02-28
CN109312351B9 (zh) 2020-10-23
EP3449003A1 (fr) 2019-03-06
EP3449003B1 (fr) 2021-03-17
CN109312351A (zh) 2019-02-05
AU2017256071A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
ES2921531T3 (es) Formulaciones para vacunas contra la neoplasia
MA39390A1 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
MA39096B1 (fr) Anticorps spécifiques à fcrn
EA201591688A1 (ru) Усовершенствованные вакцины против вируса папилломы человека и способы их применения
Borthwick et al. Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines
EA201892443A1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
BR112016026651A2 (pt) evolução de vesículas semelhantes a vírus de alta titulação para aplicações de vacina
MA42656A (fr) Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine
Trindade et al. Serro 2 virus highlights the fundamental genomic and biological features of a natural vaccinia virus infecting humans
MA43503A1 (fr) Arn viral simple brin isole (ssrna) derive du genome du virus de la peste equine (ahsv) pour la vaccination d'animaux contre le ahsv
Sonowal et al. Genome-wide expression analysis reveal host genes involved in immediate-early infections of different sheeppox virus strains
EA201890274A1 (ru) Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы
EA201792237A1 (ru) Фармацевтические составы
Viana Invenção et al. Development of synthetic antigen vaccines for COVID-19
O’Shea et al. Changing face of vaccination in immunocompromised hosts
Roper Poxvirus safety analysis in the pregnant mouse model, vaccinia, and raccoonpox viruses
David Principles of the technological analysis and diagnostic criterias of the Mesolithic techniques
Mueller-Jourdan The metaphysical position of the divine as ‘desirable’in Proclus’ Platonic theology and Maximus Confessor’s thought
Brun Vaccine technologies for veterinary viral diseases
Dai et al. Predominance of positive epistasis among resistance-associated mutations in HIV-1 protease
WO2015130488A3 (fr) Peptides associés à la classe i de cmh pour le prévention et le traitement d'une infection par le virus de l'hépatite b
RU2015148624A (ru) Генетическая конструкция рБТШ70 для экспрессии основного человеческого стресс белка, используемого в терапевтических целях, в молоке и линия трансгенных мышей, содержащих данную конструкцию
Cosseddu et al. Adaptation in cell culture determines genetic variability in the proteins of Peste des petits ruminants virus.
Kovalchuk et al. Achievements of the FSBI CEERB in Veterinary Medicine and Reproductive Biotechnology
RU2016103824A (ru) Способ повышения эффективности вакцинации крупного рогатого скота против вирусных инфекционных заболеваний